MedPath

Impact of C-arm CT in Decreased Renal Function Undergoing TACE for Tx of Hepato-Cellular Carcinoma

Terminated
Conditions
Kidney (Renal Cell) Cancer
Registration Number
NCT01326390
Lead Sponsor
Stanford University
Brief Summary

Impact on contrast dose or total volume of contrast required to effectively treat the targeted tumor.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
13
Inclusion Criteria
  1. Patients must be affected by HCC
  2. Patients must have diminished renal function (GFR<60 ml/min/1.73m^2)
  3. Patients must be 18 years old or older
  4. Patients must have received an abdominal CT, PET/CT scan or MRI, completed prior to the TACE procedure.
  5. Ability to understand and the willingness to sign a written informed consent document.
Read More
Exclusion Criteria
  1. Subjects under the age of 18
  2. Patients currently on dialysis
  3. Pregnant women
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Proportion of patients that develop renal failure (defined as a decline of renal function, as measured by glomerular filtration rate, of 25% or more from pre-procedural)3 weeks
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Stanford University School of Medicine

🇺🇸

Stanford, California, United States

© Copyright 2025. All Rights Reserved by MedPath